GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of dose escalation — my 16-week log, condensed into one table — 68 comments in the full submission. View in context.
6k
c/retatrutide·submitted 1 year ago by u/viktor_laurent

dose escalation — my 16-week log, condensed into one table

Questionbranch of 6 comments

The title is the argument: dose escalation — my 16-week log, condensed into one table. Here is the rest of it. It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it. The standing caveat, written…

Read the full submission and all 68 comments →

This branch

6 comments, started 1 year ago
u/niels_lindqvist930 points·1 year ago

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

replysharereportpermalink
u/reta_and_regretMOD490 points·1 year ago

Trial names corrected in the title. The phase 3 programme and the phase 2 readout are not the same thing.

replysharereportpermalink
u/deleted_my_history215 points·1 year ago

research-use-only material is not approved for human use, full stop

replysharereportpermalink
[removed]338 points·1 year ago

[removed by moderator]

replysharereportpermalink
u/niels_lindqvist-29 points·1 year ago

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

replysharereportpermalink
u/nausea_notesside effects1 point·1 year ago·edited

That is body weight change, not fat mass. The trials report the first and people quote it as the second.

replysharereportpermalink

← back to the whole thread

About c/retatrutide

Retatrutide: GIP/GLP-1/glucagon triple agonism, the TRIUMPH programme, and the fact that most people discussing it are handling research-grade material with no human-use approval anywhere. Dose-response, heart-rate signal, and the unusually steep phase-2 weight curves get argued about here weekly.

65kmembers
130submissions
Sep 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/retatrutide
c/retatrutide rules
  1. Retatrutide is not approved anywhere for human use. Posts must not read as usage instructions.
  2. Phase 2 numbers are not maintenance numbers. Cite the trial and the dose arm.
  3. Heart-rate and dose-escalation reports need actual measurements, not impressions.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/reta_and_regretu/trialwatch_theou/incretin_ivyu/ledger_mod
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →